News

August 27, 2015 6:00 pm
New England Journal of Medicine Editorial.
August 26, 2015 12:00 pm
The Leukemia & Lymphoma Society (LLS) invites you to learn about the diagnosis of myeloma, treatment, including clinical trials, side effects management, and communication with the healthcare team. View Video
August 25, 2015 5:00 pm
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine...
August 25, 2015 3:30 pm
STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, a novel, oral Selective Inhibitor of Nuclear Export / SINE™ compound, will be evaluated in...

Pages